AKBA — Akebia Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on AKBA
| date | signal | measured base rate |
|---|---|---|
| 2026-08-17 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-07 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. CEO and President | Option exercise | 350.0K | 0.63 | 220.5K |
| 2026-06-29 | Ostrowski Erik SVP, CFO, CBO & Treasurer | Open-market sale 10b5-1 plan | 56.0K | 1.11 | 62.2K |
| 2026-06-17 | Smith Cynthia Director | Grant or award | 35.7K | 0.00 | 0 |
| 2026-06-17 | ADAMS ADRIAN Director | Grant or award | 35.7K | 0.00 | 0 |
| 2026-06-17 | ZUMWALT LEANNE M Director | Grant or award | 35.7K | 0.00 | 0 |
| 2026-06-17 | Wolf Myles Director | Grant or award | 35.7K | 0.00 | 0 |
| 2026-06-17 | ROGERS MICHAEL W Director | Grant or award | 35.7K | 0.00 | 0 |
| 2026-06-17 | FRIESON RON Director | Grant or award | 35.7K | 0.00 | 0 |
| 2026-03-04 | Butler John P. CEO and President | Open-market purchase | 69.3K | 1.25 | 86.6K |
| 2026-02-02 | Butler John P. CEO and President | Grant or award 10b5-1 plan | 175.2K | 1.41 | 247.1K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 26.0M | 18.7M |
| STATE STREET CORP | 16.1M | 11.6M |
| VANGUARD CAPITAL MANAGEMENT LLC | 15.5M | 11.2M |
| GEODE CAPITAL MANAGEMENT, LLC | 9.0M | 6.5M |
| GOLDMAN SACHS GROUP INC | 5.0M | 3.6M |
| CITIGROUP INC | 4.0M | 2.9M |
| BANK OF AMERICA CORP /DE/ | 3.8M | 2.8M |
| Qube Research & Technologies Ltd | 3.3M | 2.4M |
| MILLENNIUM MANAGEMENT LLC | 3.3M | 2.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | 2.2M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about AKBA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →